Influence of CYP1A1 polymorphism on clinical outcomes of CRC patients treated by oxaliplatin plus capecitabine

doi:10.12092/j.issn.1009-2501.2018.02.008

Abstract

Abstract:

AIM: To investigate whether gene variants of cytochrome P450 (CYP450) affected clinical outcomes of oxaliplatin plus capecitabine in colorectal cancer (CRC). METHODS: Sixty-nine CRC patients who were treated with oxaliplatin plus capecitabine were included in this study. And 79 SNPs in CYP450, whose minor allele frequency (MAF) were >10% were genotyped. Association between the SNP and clinical outcomes were analyzed. RESULTS: Only one SNP, CYP1A1 rs1048943 was significantly associated with PFS (P=0.000 3). Multivariate analysis confirmed its prognostic significance for PFS (P=0.004). CONCLUSION: CYP1A1 rs1048943 polymorphism is probably a potential prognostic marker for survival outcome treated with oxaliplatin plus capecitabine chemotherapy in CRC patients.

Key words: colorectal cancer, CYP450, polymorphism

CLC Number:

R735.3+5

XIAO Peng, MEI Jiazhuan, BAI Hua, LI Min, LIU Guiju, LI Ruijun, SHEN Jie. Influence of CYP1A1 polymorphism on clinical outcomes of CRC patients treated by oxaliplatin plus capecitabine[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(2): 159-164.

References

［1］Loree JM, Kopetz S. Recent developments in the treatment of metastatic colorectal cancer［J］. Ther Adv Med Oncol,2017,9(8):551-564.
［2］Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015［J］. CA Cancer J Clin, 2016,66(2):115-132.
［3］Stintzing S, Tejpar S, Gibbs P, et al. Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes［J］. Eur J Cancer,2017,84:69-80.
［4］周密，邱峰，张渊，等. 美洛昔康对人结肠癌细胞增殖、迁移和PTEN基因表达的影响［J］. 中国药理学通报,2015,31(12):1704-1709.
［5］Aparicio T, Francois E, Cristol-Dalstein L, et al. PRODIGE 34-FFCD 1402-ADAGE: Adjuvant chemotherapy in elderly patients with resected stage III colon cancer: A randomized phase 3 trial［J］. Dig Liver Dis,2016,48(2):206-207.
［6］Lonardi S, Sobrero A, Rosati G, et al. Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial［J］. Ann Oncol, 2017，27(11):2074-2081.
［7］Ingelman-Sundberg M, Sim SC, Gomez A, et al. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects［J］. Pharmacol Ther, 2007, 116(3):496-526.
［8］Watson RG, Mcleod HL. Pharmacogenomic contribution to drug response ［J］. Cancer J, 2011,17(2):80-88.
［9］Zhang DY, Yuan XQ, Yan H, et al. Association between DCK 35708 T>C variation and clinical outcomes of acute myeloid leukemia in South Chinese patients ［J］. Pharmacogenomics, 2016, 17(14):1519-1531.
［10］Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future［J］. Trends Pharmacol Sci, 2004, 25(4):193-200.
［11］Oztas E, Ozhan G, Daly AK. The effect of the CYP1A1*2A allele on colorectal cancer susceptibility in a British population［J］. Genet Test Mol Biomarkers, 2016, 20(8):475-477.
［12］Sun H, Wang C, Hao M, et al. CYP24A1 is a potential biomarker for the progression and prognosis of human colorectal cancer［J］. Hum Pathol, 2016, 50:101-108.
［13］Wang H, Ren L, He Y, et al. Association between cytochrome P4502C9 gene polymorphisms and colorectal cancer susceptibility: evidence from 16 case-control studies ［J］. Tumor Biol, 2014, 35(5):4317-4322.
［14］Ribrag V. Towards common response evaluation criteria for solid tumors and lymphomas: RECIL and RECIST ［J］ ? Ann Oncol, 2017, 28 (7), 1409-1411.
［15］Trumpi K, Ubink I, Trinh A, et al. Neoadjuvant chemotherapy affects molecular classification of colorectal tumors［J］. Oncogenesis,2017,6(7):e357.
［16］Dong N, Meng F, Wu Y, et al. Genetic polymorphisms in cytochrome P450 and clinical outcomes of FOLFIRI chemotherapy in patients with metastatic colorectal cancer［J］. Tumor Biol,2015,36(10):7691-7698.
［17］Yeh CC, Lai CY, Chang SN, et al. Polymorphisms of MTHFR C677T and A1298C associated with survival in patients with colorectal cancer treated with 5-fluorouracil-based chemotherapy［J］. Int J Clin Oncol,2017,22(3):484-493.
［18］Patricia RC, Janeth RC, Alonso LY, et al. Thymidylate synthase polymorphism in Mexican patients with colon cancer treated with 5-fluorouracil［J］. J Buon,2016,21(4):935-940.
［19］Cosma G, Crofts F, Taioli E, et al. Relationship between genotype and function of the human CYP1A1 gene［J］. J Toxicol Environ Health,1993,40(2/3):309-316.
［20］Kaida Y, Inui N, Suda T, et al. The CYP2A6*4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer［J］. Clin Pharmacol Ther, 2008, 83(4): 589-594.
［21］Zeng Z, Liu Y, Liu Z, et al. CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis［J］. Cancer Chemother Pharmacol, 2013, 72(2): 287-303.
［22］Chen Z, Li Z, Niu X, et al. The effect of CYP1A1 polymorphisms on the risk of lung cancer: a global meta-analysis based on 71 case-control studies［J］. Mutagenesis,2011,26(3):437-446.
［23］Sergentanis TN, Economopoulos KP. Four polymorphisms in cytochrome P450 1A1 (CYP1A1) gene and breast cancer risk: a meta-analysis［J］. Breast Cancer Res Treat, 2010,122(2):459-469.

[1]	LI Qinghua, ZHAO Yan, ZHAO Haigang, GAO Pengfei, XU Bingxin. Value of ABCB1 G2677T gene polymorphism detection in lipid-lowering therapy with atorvastatin in patients suffered from ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 633-640.
[2]	ZHU Li, WEI Bing, LIAO Shi'e, ZHANG Chao, ZHENG Xiaoyu, LIU Yajun. Effects of single nucleotide polymorphism of drug metabolizing enzyme cytochrome P450 on the efficacy of inhaled cortisol hormone in asthmatic children [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 536-543.
[3]	SHI Dawei, ZHENG Xiaoyong, JIN Xiaodan, ZHAO Xiaoman, CHEN Jie, DU Xingjun. Implication of XPC rs2228001 polymorphism on the prognosis of patients with colorectal cancer who were treated with capecitabine-based adjuvant chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 391-399.
[4]	ZHOU Jing, ZHOU Chen, LIAO Ke, QIU Ailin, DONG Weilei, GUO Zifen. Correlation between progesterone receptor G1978T polymorphism and endometrial cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 400-406.
[5]	ZHANG Zhiying, JIN Xiuhong, ZHANG Xiaoning, ZHANG Xiangfeng, LUO Qinglin, ZHANG Songlin. Clinical study of TBX21 and ADCY9 polymorphisms in the develop- ment of childhood asthma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 407-412.
[6]	WEI Zhenzhen, SUI Hua, JIANG Yulang, SUN Mingyu, YAN Huaru, WANG Ziyuan. Research on the molecular mechanism of Zuo Jin Wan combined with cetuximab inducing ferroptosis in KRAS mutant colorectal cancer cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 130-137.
[7]	LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang. Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282.
[8]	WANG Shuang, LIU jia, ZHANG Yueli. Associations of POR*28 polymorphisms with tacrolimus stable dose in Chinese kidney transplantation patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 991-997.
[9]	FU Hong, TIAN Lei. Individualized precision therapy for patients with ischemic stroke and hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 870-876.
[10]	CHEN Wengang, YIN Qin, ZHANG Weiwei, ZHOU Lulu, KOU Wanqing, YUAN Xiaolong. Distributions of MTHFR gene polymorphism and its correlation with blood Hcy in patients with hypertension in southern Anhui province [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 768-774.
[11]	WU Yuanzhu, LIU Jun, YANG Kui, PENG Jing, LUAN Jiajie, WEI Jun, ZHANG Dafa, SONG Shuai, YUAN Xiaolong, WANG Zhongfang, ZHANG Nianbao, XIE Dan, JIANG Peng, FAN Jie. Distribution of CYP2C9*3 and VKORC1-1639G>A gene polymorphism in Anhui Han population and their influence on the stable dose of warfarin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 652-659.
[12]	ZHOU Guangchen, LIU Yixi, ZHENG Yun. Colorectal cancer and microRNA: research progress [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 575-587.
[13]	CHEN Jiayin, WANG Li, WANG Lijun, TONG Gangling, MA Jie, CHEN Xijing, LU Yang. Correlation between organic cation transporter gene polymorphisms and the toxicities and clinical response of oxaliplatin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 171-177.
[14]	LI Yanyan, FANG Xiaojie, YIN Xin, SUN Xi, RAO Chunhui. circZNF124 regulates the proliferation, migration and invasion of colorectal cancer SW620 cells by targeting miR-4262 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1231-1239.
[15]	ZHOU Minmin, YU Lu, HAN Chao, GU Damin, LEI Daoyun. Relationship between human cholesteryl ester transfer protein rs5882 gene polymorphism and postoperative cognitive dysfunction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 768-774.